Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 30.11M P/E - EPS this Y 35.90% Ern Qtrly Grth -
Income -35.2M Forward P/E -1.89 EPS next Y 6.10% 50D Avg Chg -86.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -88.00%
Dividend N/A Price/Book 0.76 EPS next 5Y - 52W High Chg -95.00%
Recommedations 2.50 Quick Ratio 1.32 Shares Outstanding 10.22M 52W Low Chg -
Insider Own 45.08% ROA -89.70% Shares Float 5.39M Beta -
Inst Own 5.31% ROE -346.95% Shares Shorted/Prior 39.52K/28.41K Price 1.00
Gross Margin - Profit Margin - Avg. Volume 9,514 Target Price 11.00
Oper. Margin - Earnings Date May 8 Volume 224,803 Change 0.00%
About Angion Biomedica Corp.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.

Angion Biomedica Corp. News
04/25/24 Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
04/13/24 Robert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO is the most bullish insider, and their stock value gained 11%last week
04/05/24 Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
03/29/24 Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
03/18/24 Elicio Therapeutics Announces $6.0 Million Private Placement Financing
03/06/24 Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
02/05/24 Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/25/24 Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
01/17/24 Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
01/16/24 Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
01/11/24 Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
01/09/24 Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
12/22/23 Elicio Therapeutics Announces $7.0 Million Private Placement Financing
12/04/23 Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
11/09/23 Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
11/03/23 Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
10/11/23 Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
09/27/23 Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
09/07/23 Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
09/06/23 Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
ELTX Chatroom

User Image truehealthvalue Posted - 04/25/24

$ELTX dynamics have completely changed on eltx. Xbi down 3% and ELTX flat, there must be something with real value

User Image Stock_Titan Posted - 04/25/24

$ELTX Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting https://www.stocktitan.net/news/ELTX/elicio-therapeutics-to-present-new-preliminary-data-from-the-ongoing-hq94y1mwfx36.html

User Image Nosh Posted - 04/24/24

$ELTX This one is intriguing but looks like a handle to at least $8...will look for entry there.

User Image QuantumCapital Posted - 04/14/24

$ELTX

User Image Simpson216 Posted - 04/11/24

$ELTX

User Image Scooter0732 Posted - 04/11/24

$ELTX this is becoming interesting

User Image Benzinga Posted - 04/10/24

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry $ELTX https://www.benzinga.com/partner/biotech/24/04/38180627/elicio-therapeutics-nasdaq-eltx-makes-strides-in-growing-cancer-vaccination-industry

User Image Fullratio Posted - 04/07/24

$ELTX total assets is 72% greater than its total liabilities: https://fullratio.com/stocks/nasdaq-eltx/elicio-therapeutics

User Image axelvento999 Posted - 04/05/24

$ELTX news out: https://elicio.com/press_releases/elicio-therapeutics-to-present-updated-clinical-t-cell-and-antigen-spreading-response-data-from-the-ongoing-amplify-201-phase-1-study-of-eli-002-and-preclinical-data-on-eli-007-and-eli-008-at-the-aacr/

User Image Stock_Titan Posted - 04/05/24

$ELTX Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting https://www.stocktitan.net/news/ELTX/elicio-therapeutics-to-present-updated-clinical-t-cell-and-antigen-48m3jfq67bgp.html

User Image Stonksyo Posted - 04/05/24

$ELTX

User Image Benzinga Posted - 04/04/24

Unlocking The Power Of Immunotherapy: Elicio Therapeutics' (NASDAQ: ELTX) Novel AMP Platform $ELTX https://www.benzinga.com/partner/biotech/24/04/38088328/unlocking-the-power-of-immunotherapy-elicio-therapeutics-nasdaq-eltx-novel-amp-platform

User Image matthew122 Posted - 04/04/24

$ELTX this ranks in the top shittiest companies I know

User Image AnalRetort Posted - 4 weeks ago

$ELTX why is this skywalking? Doesn't gritstone bio's recent results question the entire thesis? Since Gritstone's cancer vax did nothing in terms of os, and ctdna clearance which can be explained from chemo alone. How do we know if $ELTX cancer vax ctdna clearance results are not from the chemo?

User Image Stock_Titan Posted - 03/29/24

$ELTX Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates https://www.stocktitan.net/news/ELTX/elicio-therapeutics-reports-2023-financial-results-and-provides-0gxqusnq67qa.html

User Image BadWolfRose Posted - 03/28/24

$ELTX My eyes did Not deceive me 😍🤑

User Image Woooehoo Posted - 03/25/24

$ELTX when is this thing moving

User Image axelvento999 Posted - 03/19/24

$ELTX announced today that it has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81

User Image Pfreakstocks Posted - 03/18/24

@SadyK189 what do you think of $ELTX or $UPC ?

User Image Stocksrunner Posted - 03/18/24

🚀📈💥 MONDAY MARKET MOVERS! 💥📈🚀 🔥 Get ready for some adrenaline-pumping action as the market opens with these top gainers dominating the headlines! 🔥 1️⃣ $SMR Alphabet, Nvidia, PepsiCo, and more leading the charge higher! 🚀 Dow Jones up 100 points! 📈 Alphabet shares soaring 6.3% to $150.09! 📈 2️⃣ $ELTX making waves with a $6.0 million private placement financing announcement! 🌊💰 3️⃣ $CGC Marijuana stocks like Tilray and Canopy Growth rallying on DEA rescheduling chatter! 🌿📈 4️⃣ $SHCO Soho House skyrockets on reports of a takeover offer! 🏠🚀 5️⃣ $XGN reports strong Q4 results, exceeding revenue estimates! 💪💼

User Image _StockTrader Posted - 03/18/24

Real-Time Stock Data $ELTX Price: 5.5 Volume: 260929 Market Cap: 59660692 PE Ratio: -2.3980696 Powered by: OZSC

User Image tradingtwenty Posted - 03/18/24

$ELTX has trended 4 times in the past 24 hours (based on 5 minute intervals). Latest article on Mar 18, 2024 08:00 AM: Elicio Therapeutics Announces $6.0 Million Private Placement Financing Link: https://tradingtwenty.com/news/398085/elicio-therapeutics-announces-60-million-private-placement-financing

User Image RockyTSTH Posted - 03/18/24

$ELTX Elicio Therapeutics shares are trading higher. The company announced a $6 million private placement financing to purchase up to 1,032,702 shares at $5.81 per pre-funded warrant.

User Image Simpson216 Posted - 03/18/24

$ELTX

User Image truehealthvalue Posted - 03/18/24

$ELTX warrants at a primium… something is cooking

User Image DonCorleone77 Posted - 03/18/24

$ELTX Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing Elicio Therapeutics has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81 per pre-funded warrant in a private placement to GKCC, LLC. GKCC, LLC is an entity controlled by a member of Elicio's Board of Directors. Each pre-funded warrant will be exercisable at any time on or after the closing date at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the pre-funded warrant, subject to a post-exercise beneficial ownership limitation of 19.99%, unless stockholder approval is obtained. Gross proceeds of the private placement are expected to be approximately $6.0 million, before deducting expenses. The private placement is expected to close on March 19, 2024, subject to the satisfaction of customary closing conditions....

User Image Stock_Titan Posted - 03/18/24

$ELTX Elicio Therapeutics Announces $6.0 Million Private Placement Financing https://www.stocktitan.net/news/ELTX/elicio-therapeutics-announces-6-0-million-private-placement-5d005b3ru93f.html

User Image Pfreakstocks Posted - 03/15/24

$ELTX $NVDA

User Image QuantumCapital Posted - 03/13/24

$ELTX BTW, support is 4.65, may head there first before heading higher, current price is 5.48, not what it is currently showing here.

User Image QuantumCapital Posted - 03/13/24

$ELTX Good potential for short term return, 5 of 6 buy signal, PT to 8.00 (+40%), up to 11.00 to 13.50 range (90% up to +135%) potential, one to eight weeks, gl.

Analyst Ratings
HC Wainwright & Co. Buy May 1, 24
Oppenheimer Perform Apr 1, 24
HC Wainwright & Co. Buy Jan 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chudnovsky Yekaterina Director Director Dec 22 Buy 5.81 1,213,000 7,047,530 1,915,639 12/26/23
Venkatesan Jay See Remarks See Remarks May 20 Buy 1.24 82,200 101,928 1,721,457 05/25/22
Nissenson Allen Director Director May 19 Buy 1.17 9,383 10,978 9,383 05/23/22
Venkatesan Jay See Remarks See Remarks Dec 16 Buy 2.55 41,625 106,144 1,358,486 12/20/21